Odyssey Therapeutics, Inc. filed a Current Report on Form 8-K with the Securities and Exchange Commission on September 8, 2026, to confirm the posting of a corporate presentation on its website. The filing, submitted from the company’s principal executive offices at 51 Sleeper Street, Suite 800 in Boston, Massachusetts, indicates that the presentation was furnished as Exhibit 99.1 to the report.
The attached presentation, dated September 2026, contains highly confidential information regarding the company and its subsidiaries. It includes forward-looking statements regarding the company’s business strategy, the future clinical development of its product candidates, and expectations regarding regulatory approval and financial results. The filing notes that the information furnished in Item 7.01 and Exhibit 99.1 shall not be deemed "filed" for purposes of the Exchange Act and is not incorporated by reference into other filings.
The presentation outlines Odyssey’s strategy for targeting inflammatory and autoimmune diseases, specifically focusing on the potential to unlock durable remissions by targeting upstream signaling. The company states that its portfolio is lean and agile, with multiple programs at the development candidate stage or later. Key programs mentioned include OD-001, a small molecule targeting RIPK2 for inflammatory bowel disease (IBD); OD-002, a small molecule targeting SLC15A4 for cutaneous lupus erythematoses and B cell-mediated diseases; and OD-003, a protein agonist targeting TNFR2 for atopic dermatitis and systemic lupus erythematosus.
The company also disclosed its financial position, noting a cash balance of $433 million as of June 30, 2026. Odyssey stated that this cash balance is expected to fund operations into the second half of 2028. The presentation highlights anticipated upcoming clinical milestones, including updated monotherapy data for OD-001 at the United European Gastroenterology Week in October 2026 and the initiation of Phase 1/2 studies for OD-002 in the first half of 2027.
